
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a biotechnology company with a strong focus on developing simple and cost-effective blood tests for the diagnosis and monitoring of diseases associated with NETosis. The recent publication of a peer-reviewed clinical study conducted with the Mayo Clinic provides additional validation for the company's Nu.Q platform, particularly in acute care settings. While this is a positive development, the company still faces risks in terms of clinical adoption, regulatory clarity, and integration into clinical workflows before it can generate meaningful revenue.
Bears say
VolitionRX is facing multiple negative factors, including a recent reverse stock split that raises concerns about financial stress and business strength. In addition, the company's ongoing focus on capital structure and exchange compliance may overshadow any clinical progress, making it difficult for the stock to gain positive momentum. Furthermore, the company may need to raise additional capital to fund operations beyond mid-2026, which could further dampen investor confidence.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares